The LBI-HTA in Austria published 7 HTA reports relevant for medical devices in 2017; none of the technologies was recommended for inclusion without limitations

07

Feb 2018

The Ludwig Boltzmann Institute– Health Technology Assessment (LBI-HTA) is the main health technology appraisal body in Austria. It is an independent organization that on request provides scientific support for decision-making regarding the inclusion of health technologies (medical devices and in-vitro diagnostics) into the national benefit catalogue by the Ministry of Health. LBI-HTA produces different types of reports. The most relevant reports regarding market access of medical devices are so-called decision support documents (DSD) which are systematic, scientific review papers with a focus on efficacy and safety of technology (HTA reports).

In decision support documents, the LBI-HTA gives its evidence-based recommendation in the form of four categories:

  1. Recommendation for inclusion
  2. Limmited recommendation for inclusion
  3. Preliminary no recommendation for inclusion
  4. No recommendation for inclusion

Recommendations by the LBI-HTA are not binding, yet, they are in 90 % of cases followed by the decision maker, the Federal Health Commission (BGK).

During the year 2017, the LBI-HTA produced seven decision support documents with relevance for medical devices of which 2 were updates of previous reports. Following were the report titles and LBI-HTA’s recommendation expressed in category numbers described above:

  • Extracorporeal cytokine haemadsorption therapy in patients with sepsis or SIRS; 3
  • Prostate artery embolisation for benign prostatic hyperplasia; 3
  • Radiofrequency ablation for metastatic spinal lesions; 2
  • Electric stimulation therapy (EST) in patients with gastroesophageal reflux disease (GERD); 3
  • Leadless pacemakers for right ventricle pacing, update; 3
  • Repetitive transcranial magnetic stimulation for treatment-resistant major depression; 2
  • Percutaneous volume reduction of the disc with focus on chemonucleolysis, update
    • Recommendation for chemonucleolysis: 2
    • Recommendation for further percutaneous intervertebral disk volume reduction (percutaneous nucleotomy, percutaneous laser disc decompression or IDET): 3

All reports published in 2017 are available in the LBI-HTA repository.

Subscribe to our newsletter delivered every second week not to miss important reimbursement information.

The latest related news

24

Mar 2022

The HTA body of the Tuscany Regional Healthcare issues two types of documents: HTA forms and motivational forms. With a regional decree 2472 of February 10, 2022, Tuscany Regional Healthcare has published assessments of five medical devices of various therapeutic areas, such as cardiovascular and peripheral vascular areas.

Read more

15

Mar 2022

The Belgian Health Care Knowledge Center (KCE) initiated a study aimed at defining a clear and transparent procedure for the evaluation of digital health technologies in Belgium.

Read more

11

Mar 2022

On February 07, 2022, the Dental and Pharmaceutical Benefits Agency has announced the withdrawal of the assessments of the PhysioMem PM 100 and CardioMem CM 100 XT and the finalization of the assessments of the Zenicor ECG, Coala Heart Monitor Pro, and KardiaMobile. For the conducted assessments, it was outlined that the portable devices provide more limited information than standard ECG measurements; therefore, it was mainly estimated for atrial fibrillation.

Read more

10

Mar 2022

In February 2022, the Finnish Coordinating Center for Health Technology Assessment announced the release of the seven accomplished rapid hospital assessments performed by the Helsinki, Tampere, and Oulu University Hospital. The accomplished rapid HTAs concern the diagnostic imaging, e-Health, endocrine, endoscopy, men’s health, neuromodulation technology groups.

Read more

08

Mar 2022

At the end of February 2022, the Dental and Pharmaceutical Benefits Agency (TLV) has launched a theme survey on products for monitoring and diagnostics of sepsis to identify products that may be relevant for health economic assessments at TLV. The suggestions for the products of interest, ongoing clinical studies, or innovation projects could be received until 23 March 2022.

Read more